Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out how to Detect the Best Rooftop Substitution Choices - 2How mountain terraces have helped Indigenous peoples live with climate uncertainty
- 3Pocket-Accommodating Jeep Wrangler Buying Guide for Seniors
- 4The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- 5A definitive Manual for Well known Fragrances
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- 6 Modest and Strong Tire Brands
- My Excursion to Monetary Autonomy: Awesome ways to save cash
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Dominating Capable Mastercard Utilization: Key Contemplations
